Complete response in patient with liver metastasis of HER2-positive breast cancer following therapy with margetuximab: a case report

被引:1
|
作者
Chang, Haiyan [1 ]
Hu, Ting [1 ]
Hu, Jie [1 ]
Ding, Teng [2 ]
Wang, Qiong [1 ,3 ]
Cheng, Jing [1 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China
[2] Zai Lab Shanghai Co Ltd, Med Affairs Dept, Shanghai, Peoples R China
[3] Huazhong Univ Sci & Technol, Dept Oncol, Union Hosp, Tongji Med Coll, 109 Machang Rd, Wuhan, Hubei, Peoples R China
关键词
breast cancer; human epidermal growth factor receptor 2; liver metastasis; margetuximab; TRASTUZUMAB; POLYMORPHISMS; BENEFIT;
D O I
10.1097/CAD.0000000000001466
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer has a poor prognosis and few effective targeted therapies. However, several anti-HER2 agents are emerging in conjunction with chemotherapy, which may lead to increased rates of pathological complete response in patients with HER2-positive metastatic breast cancer. Among them, margetuximab demonstrated a significant improvement in progression-free survival compared with trastuzumab, when combined with chemotherapy in pretreated patients. Here we present a case of a 67-year-old female patient who was diagnosed with HER2-positive, histological grade III and invasive ductal carcinoma of the left breast in September 2018. She received postoperative adjuvant therapy with EC-TH plus radiotherapy, followed by therapy with HER2-targeted trastuzumab for 1 year (till December 2019). In May 2020, routine reexamination showed a supraclavicular lymph node and bone metastasis. Patient was then treated with pyrotinib, capecitabine and bisphosphonate for a period of 3 months. In December 2020, liver MRI revealed multiple liver metastases. The patient received eight cycles of second-line therapy (vinorelbine plus margetuximab) from January 2021. Since the ninth cycle, the patient was continued with only margetuximab. In March 2021, MRI showed a 70% decrease in the liver metastasis lesions. By June 2021, liver lesions were totally disappeared. During therapy, patient experienced only grade-1 anemia. This case demonstrates that margetuximab plus chemotherapy is safe and might bring clinical benefits for patients with HER2-positive breast cancer with liver metastasis. Further studies evaluating the efficacy and safety of margetuximab in Chinese HER2-positive breast cancer patients are needed.
引用
收藏
页码:883 / 887
页数:5
相关论文
共 50 条
  • [31] Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report
    Montagna, E.
    Cancello, G.
    Torrisi, R.
    Rizzo, S.
    Scarano, E.
    Colleoni, M.
    ANNALS OF ONCOLOGY, 2010, 21 (03) : 667 - U238
  • [32] Effectiveness of trastuzumab deruxtecan rechallenge in a patient with HER2-positive metastatic breast cancer: a case report
    Tanaka, Yuko
    Ikeda, Naoya
    Niho, Seiji
    Ishida, Kazuyuki
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2024, 13 (04): : 353 - 359
  • [33] Clinicopathological Factors Predicting Pathological Complete Response to Neoadjuvant Anti-HER2 Therapy in HER2-Positive Breast Cancer
    Jung, Youn Joo
    Lee, Seungju
    Kang, Seok Kyeong
    Kim, Jee Yeon
    Choo, Ki Seok
    Nam, Kyung Jin
    Joo, Ji Hyeon
    Kim, Jae Joon
    Kim, Hyun Yul
    ONCOLOGY, 2024,
  • [34] HER2-positive breast cancer metastatic to intracranial meningioma: a case report
    McCormack, Mikkaela
    Salinas-La Rosa, Cesar
    Murphy, Michael
    Fox, Stephen B.
    JOURNAL OF CLINICAL PATHOLOGY, 2013, 66 (07) : 633 - 634
  • [35] HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature
    Gevorgyan, Arpine
    Bregni, Giacomo
    Galli, Giulia
    Zanardi, Elisa
    de Braud, Filippo
    Di Cosimo, Serena
    BREAST CARE, 2016, 11 (06) : 424 - 426
  • [36] Margetuximab Anti-HER2 monoclonal antibody Treatment of metastatic HER2-positive breast cancer Treatment of HER2-positive gastric or gastroeso-phageal junction cancer
    Hanna, K. S.
    DRUGS OF THE FUTURE, 2021, 46 (03) : 191 - 195
  • [37] Dramatic Response to Trastuzumab Deruxtecan Rechallenge in a Patient with HER2-Positive Gastric Cancer: A Case Report
    Ogata, Takatsugu
    Fujita, Yasuko
    Muro, Kei
    AMERICAN JOURNAL OF CASE REPORTS, 2022, 23
  • [38] Significant response to the combination of pyrotinib and letrozole in a patient with metastatic HER2-positive and hormone receptor-positive breast cancer: a case report
    Li, Jing
    Shui, Zhengrong
    Ouyang, Quchang
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (09) : 10124 - 10129
  • [39] Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC)
    Loibl, Sibylle
    Untch, Michael
    Buyse, Marc
    Robidoux, Andre
    Gianni, Luca
    Schneeweiss, Andreas
    Conte, Pierfranco
    Piccart, Martine
    Bonnefoi, Herve
    Jackisch, Christian
    Nekljudova, Valentina
    Costantino, Joseph
    Valagussa, Pinuccia
    Neate, Colin
    Gelber, Richard
    Poncet, Coralie
    Squifflet, Pierre
    Saad, Everardo
    Heinzmann, Dominik
    Denkert, Carsten
    Geyer, Charles E., Jr.
    Cortes, Javier
    Guarneri, Valentina
    de Azambuja, Evandro
    Cameron, David
    Ismael, Gustavo
    von Minckwitz, Gunter
    Wolmark, Norman
    Cortazar, Patricia
    CANCER RESEARCH, 2020, 80 (04)
  • [40] Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report
    Xie, Ning
    Liu, Liping
    Tian, Can
    Hu, Zheyu
    Ouyang, Quchang
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (16)